Medidata RTSM vs YPrime IRT(RTSM / IRT)

Sponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.

Scope Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.

Guide updated How we compare

Compare within RTSM / IRT

Study fit, side by side

These notes describe the products in the RTSM / IRT guide.

Medidata RTSM

Best for
Sponsors already on Rave EDC who want randomization and supply in the same system
What to consider
Medidata RTSM is unified with Rave EDC, so randomization and dispensing data do not need reconciling between two systems. Its fact sheets document block, stratified and dynamic allocation, supply forecasting, direct-to-patient shipping and post-go-live changes with little to no downtime. Pricing is not published.
Read product profile

YPrime IRT

Best for
Sponsors with complex randomization schemes, including minimization, who may also use YPrime eCOA
What to consider
YPrime names more randomization methods than any other vendor here, from permuted blocks to Pocock-Simon minimization, and publishes short build times. Its public IRT page does not describe supply forecasting or direct-to-patient shipping, and we found no named security certification.
Read product profile

Compare the features

Both products use the same category definitions. Product order is editorial; products are not ranked.

Full RTSM / IRT feature comparison

Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.

Expand a feature definition or support note for context and its original source.

Medidata RTSM vs YPrime IRT (RTSM / IRT): category feature evidence and sources. Products are not ranked.
Category featureMedidata RTSMYPrime IRT
Randomization and blinding
Feature definitions
Supported
Randomization or blinding workflows are stated.
Extended support
Named allocation methods include minimization or dynamic allocation.
Extended support

A Medidata fact sheet lists pre-validated permuted block and dynamic allocation, stratification, cohort management, titration and a randomization simulator (fact sheet dated May 2019).

Source
About this support label

Named methods include permuted blocks and dynamic allocation with stratification.

Extended support

YPrime names permuted block and stratified randomization, dynamic allocation and minimization (Pocock and Simon), stratum caps and conditional re-randomization.

Source
About this support label

Named methods include permuted blocks, dynamic allocation and minimization.

Trial supply management
Feature definitions
Supported
Drug inventory, dispensing, shipping or resupply workflows are documented.
Extended support
Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Extended support

The current fact sheet documents buffer and predictive supply schemes, forecasting that simulates future patient needs, direct-to-patient shipments and drug pooling across studies.

Source
About this support label

Predictive supply schemes and forecasting are documented alongside direct-to-patient shipments.

Supported

The IRT page covers inventory, orders, resupply, kit replacement and depot rules, but does not describe supply forecasting or direct-to-patient shipping.

Source
About this support label

Inventory and resupply establish base support; forecasting and direct-to-patient shipping are not described.

Study build speed and mid-study changes
Feature definitions
Supported
Study setup or post-go-live study changes are described.
Extended support
Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Supported

Medidata states a 2-3 week study build, and Edit Live Design allows post-go-live changes for protocol amendments (the 2024 fact sheet adds 'little to no downtime').

Source
About this support label

A build timeline and live amendments are stated, but little-to-no downtime permits some interruption.

Supported

YPrime cites build to go-live in under four weeks for an early-phase oncology trial, about a week for the simplest designs, and self-service routine changes that take effect immediately.

Source
About this support label

Build timelines and immediately effective routine changes are stated; uninterrupted live use is not explicit.

Integrations and platform
Feature definitions
Supported
Integration or data exchange with another system or application is described.
Extended support
Integration with a clinical-trial application plus an API for integration are both stated.
Supported

RTSM is unified with Rave EDC on the Medidata Platform and uses a pre-validated two-way integration with large depot vendors.

Source
About this support label

Rave and depot integrations establish base support; an API is not stated in this note.

Supported

YPrime documents integrations with EDC, eCOA, eConsent, CTMS, labs, distribution systems and data lakes, and runs its own eCOA.

Source
About this support label

Trial-system integrations establish base support; an API is not stated in this note.

Compliance and security evidence
Feature definitions
Supported
Relevant trial compliance or security controls are stated, with their scope identified.
Extended support
Relevant trial controls and a publicly accessible ISO certificate or SOC audit report covering the product or vendor are documented.
Supported

Medidata lists an ISO 27001:2022 certificate and a SOC 2+ Type II audit, and says its position statements cover 21 CFR Part 11 and EU Annex 11 (the statements sit behind a customer login).

Source
About this support label

A certificate and audit are listed, but public document access is not established; trial statements require customer login.

Supported

YPrime's trust page lists 21 CFR Part 11, GDPR and HIPAA compliance, but we found no ISO 27001 or SOC 2 attestation.

Source
About this support label

Trial and privacy standards are stated; ISO/SOC attestation evidence was not found.

Track record
Feature definitions
Supported
Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support
Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Extended support

The RTSM page cites 124 countries supported and about 16,000 patients a month.

Source
About this support label

Product-specific monthly patient usage is reported alongside a stated country count.

Supported

YPrime reports 55,000+ sites and 300,000+ patients supported and 20+ years of IRT work, but publishes no study count.

Source

The guide update date reflects guide edits. Vendor statements are attributed in the evidence.

Keep the category in view

Compare these products with the other tools in the RTSM / IRT guide using the same feature definitions.

More RTSM / IRT comparisons featuring one of these products.